Results 31 to 40 of about 148 (67)

Safety and effectiveness of Omnitrope^® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data. [PDF]

Eur J Pediatr, 2022
Backeljauw P, Kanumakala S, Loche S, Schwab KO, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K.   +9 more
europepmc   +1 more source

Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch. [PDF]

Drug Saf, 2023
Sagi S, Anjaneya P, Kalsekar S, Kottke A, Cohen HP.   +4 more
europepmc   +1 more source

Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients. [PDF]

Drug Des Devel Ther, 2022
Miller BS, Yuen KCJ.
europepmc   +1 more source

Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. [PDF]

Ital J Pediatr, 2016
Iughetti L, Tornese G, Street ME, Napoli F, Giavoli C, Antoniazzi F, Stagi S, Luongo C, Azzolini S, Ragusa L, Bona G, Zecchino C, Aversa T, Persani L, Guazzarotti L, Zecchi E, Pietropoli A, Zucchini S.   +17 more
europepmc   +1 more source

Erratum to: Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. [PDF]

Biol Ther, 2014
Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R.   +7 more
europepmc   +1 more source

Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults). [PDF]

Pituitary, 2021
Höybye C, Beck-Peccoz P, Murray RD, Simsek S, Stalla G, Strasburger CJ, Urosevic D, Zouater H, Johannsson G.   +8 more
europepmc   +1 more source

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. [PDF]

Biol Ther, 2014
Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R.   +7 more
europepmc   +1 more source

The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries. [PDF]

BioDrugs, 2023
Klein K, Gencoglu M, Heisterberg J, Acha V, Stolk P.   +4 more
europepmc   +1 more source

Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study. [PDF]

Med Devices (Auckl), 2015
Partsch CJ, Schnabel D, Ehtisham S, Johnstone HC, Zabransky M, Kiess W.   +5 more
europepmc   +1 more source

Clinicians' Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19. [PDF]

Patient Prefer Adherence, 2021
Blair J, Warth K, Suvarna Y, Cappa M.
europepmc   +1 more source